Literature DB >> 8289505

Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system?

J Burton1, N E Kay.   

Abstract

Recent evidence of cell membrane expression of interleukin-2 receptors (IL-2R) by malignant B cells in hairy cell leukemia (HCL) and B-chronic lymphocytic leukemia (B-CLL) has lead to speculation that growth factors, such as IL-2, may play a role in the pathophysiology of these diseases. However, to date, it is not clear that IL-2 is a consistent growth factor in vitro or in vivo for malignant B cells. What then is the potential significance of membrane IL-2R on the malignant B-cell membrane? Laboratory analysis indicates that the malignant cells are the source of elevated serum levels of soluble Tac protein (sIL-2r alpha) in both diseases. Indeed, these cells spontaneously secrete sIL-2R alpha into culture medium. We speculate that the presence of an expanding mass of malignant B cells possessing high and low affinity membrane IL-2R may contribute significantly to the associated immunodeficiency seen in B-CLL. In particular, it is the cell associated high affinity IL-2R that have the greatest potential for reducing the levels of free IL-2 available to normal immune cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289505

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

Review 1.  Growth and survival of B-chronic lymphocytic leukaemia cells.

Authors:  O Söderberg
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

2.  Expression of epstein-barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428.

Authors:  D Kube; M Vockerodt; O Weber; K Hell; J Wolf; B Haier; F A Grässer; N Müller-Lantzsch; E Kieff; V Diehl; H Tesch
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

3.  Reduced IL-4 and interferon-gamma (IFN-gamma) expression by CD4 T cells in patients with chronic lymphocytic leukaemia.

Authors:  S J Hill; S H Peters; M J Ayliffe; J Merceica; A S Bansal
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

Review 4.  Mechanisms of resistance to CAR T cell therapies.

Authors:  Nathan Singh; Elena Orlando; Jun Xu; Jie Xu; Zev Binder; McKensie A Collins; Donald M O'Rourke; J Joseph Melenhorst
Journal:  Semin Cancer Biol       Date:  2019-12-19       Impact factor: 15.707

Review 5.  Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.

Authors:  Francesco Autore; Paolo Strati; Luca Laurenti; Alessandra Ferrajoli
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.